(NYSE: PEN) Penumbra's forecast annual revenue growth rate of 12.28% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.8%.
Penumbra's revenue in 2026 is $1,454,283,000.On average, 20 Wall Street analysts forecast PEN's revenue for 2026 to be $63,087,605,700, with the lowest PEN revenue forecast at $59,744,434,575, and the highest PEN revenue forecast at $67,335,399,600. On average, 19 Wall Street analysts forecast PEN's revenue for 2027 to be $71,583,193,500, with the lowest PEN revenue forecast at $66,942,085,350, and the highest PEN revenue forecast at $76,106,307,375.
In 2028, PEN is forecast to generate $81,219,392,625 in revenue, with the lowest revenue forecast at $74,808,370,350 and the highest revenue forecast at $86,332,477,875.